Product Name: NSI-189 phosphate CAS No.:   1270138-41-4 Molecular Formula:  C22H33N4O5P Molecular Weight:   464.503g/mol Purity :  9 9 %  HPLC Appearance:    White to off-white Powder Solubility : Soluble in DMSO Typical use :   Treatment Alzheimer's disease, Novel Antidepressants Standard Packing :  100gram,1kg  Shelf Life  :2 years Storage : Room temperature away from light

1.Enhance cognition and memory formation  NSI-189 phosphate powder 2.Anxiolytic properties  NSI-189 phosphate powder 3.Anti-depressive effect  NSI-189 phosphate   powder 4.Treatment of Alzheimer's and Parkinson's disease  NSI-189 phosphate powder 5.Increase coordination  NSI-189 phosphate powder 6.Improves mood  NSI-189 phosphate powder 7.Help fight fatigue  NSI-189 phosphate powder 8.Prevent oxidation within the brain  NSI-189 phosphate powder 9.Treat alcohol related brain damage  NSI-189 phosphate powder

NSI-189  is neurogenic and nootropies research agent that was developed from nicotinamide and pyrazine. Randomized controlled trials have shown that it stimulates neurogenesis or neuronal cell production in the brain. In animal studies, it has also been shown to increase the volume of hippocampus by 20% thereby reversing behavioral symptoms of depression. Such studies have shown that it may be an effective treatment for depression. It is also thought to be a promising treatment for other condition including post-traumatic stress disorder (PTSD), Alzheimer's disease and age-related cognitive problems.  

Application 

NSI-189 successfully completed a phase I clinical trial for MDD in 2011, where it was administered to 41 healthy volunteers. A phase Ib clinical trial for treating MDD in 24 patients started in 2012 and completed in July 2014, with results published in December 2015. Neuralstem is now preparing to initiate phase II clinical studies for MDD in the first quarter of 2016, with results expected in the second half of 2023. In the two clinical studies conducted thus far, NSI-189 has shown statistically significant effectiveness in reducing depressive symptoms, has been found to be safe and well-tolerated (with no major adverse effects observed), and has been found to improve cognitive deficits in depressed patients. In addition to MDD, Neuralstem intends to pursue clinical development of NSI-189 for a variety of other neurological conditions, including traumatic brain injury, Alzheimer's disease, post-traumatic stress disorder, stroke, and natural cognitive and memory decline in aging.